Forte Biosciences, Inc. (FBRX)
Healthcare · NCM
Price as at 10 Aug 2026, 18:22 UTC. Quotes are delayed.
Fundamentals
Valuation and ratings
Forte Biosciences, Inc. trades at USD76.82, which is 69% above the USD23.88 our fair value estimate puts on the business. On that measure it screens as expensive, which is not the same as saying it will fall.
Our moat model scores it 8 out of 100, which is little in the way of a moat. A moat is a structural reason competitors cannot take the profits away, and it matters more to a long holding period than any single quarter's numbers do.
FBRX dividend history
No individual payments are on record for this listing, so the current facts above are all we can honestly show.
FBRX earnings and analyst estimates
Recommendation mix, 6 published ratings
Estimates are the published analyst consensus and move often. An earnings date is scheduled, not certain, and a share tends to reprice most violently on the day itself.
About Forte Biosciences, Inc.
Forte Biosciences, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for autoimmune and autoimmune-related diseases. The company offers products, such as its lead product candidate FB102, a proprietary molecule with applications for celiac disease, vitiligo, and alopecia areata; and services, including the clinical development and management of its Phase 2 clinical trials. Forte Biosciences, Inc. was incorporated in 2007 and is based in Dallas, Texas. As of August 27, 2026, Forte Biosciences, Inc. operates as a subsidiary of argenx SE.
Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.
FBRX passes 1 of our 30 screens today
Each screen prints the exact criteria it used, and the circumstances in which it is wrong.
Super investor ownership
4 of the funds we track reported a position in their latest SEC 13F filing. Largest first:
- Israel Englander, MILLENNIUM MANAGEMENT LLC$13.92M · 0.0% of book
- Tybourne Capital, TYBOURNE CAPITAL MANAGEMENT (HK) LTD$11.80M · 38.1% of book
- Ken Griffin, CITADEL ADVISORS LLC$11.63M · 0.0% of book
- Two Sigma, TWO SIGMA INVESTMENTS, LP$285.0K · 0.0% of book
A word of warning on reading these figures: a 13F reports the market value of a holding, so a fund that traded nothing at all still appears to have sold when the price fell. We found 102 companies where the standard reading gives the opposite answer. Only the share count is honest.
Common questions
Is Forte Biosciences, Inc. (FBRX) undervalued?
Against our fair value estimate of USD23.88, FBRX at USD76.82 is 69% above fair value. That is one model's answer, not a recommendation. It is built from normalized earning power with growth capped deliberately low, which understates companies whose value is mostly future growth.
Which funds own FBRX?
4 of the institutions we track reported a position in FBRX in their most recent SEC 13F filing. A 13F is filed up to 45 days after quarter end, so it tells you what a fund held then, not what it holds now.
Where does SteadyShares get its FBRX data?
Fundamentals for FBRX come from company filings and exchange data, as listed on NCM; institutional ownership comes from SEC 13F filings. The share price shown was last refreshed on 10 Aug 2026, 18:22 UTC and is delayed. Our data quality score for this company is 67/100, which is the share of the inputs behind our scores that were actually available rather than assumed. Metrics we do not hold are left out of the page rather than estimated.
The full research page for FBRX, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.